IngredientesArabinogalactan, also known as galactoarabinan, larch arabinogalactan, and larch gum, is a biopolymer consisting of arabinose and galactose monosaccharides. Additional synonyms in the scientific and commercial literature include larch wood sugar, L-arabino-D-galactan, and stractan.
Arabinogalactans (AGs) are plant heteropolysaccharides with complex structures occasionally attached to proteins (AGPs). Arabinogalactans are high molecular weight, highly branched, water-soluble polysaccharides which contain units of D-galactose and L-arabinose. The larch-derived compound is composed of galactose and arabinose molecules in a 6:1 ratio, with a small amount of glucuronic acid. Arabinogalactans are long, densely branched polysaccharides of varying molecular weights (10,000–120,000).
Two principal structural types are recognized in the plant kingdom. AGs are categorized into two main types based on their structural backbones: Type I, predominantly composed of β-d-(1→4)-galactan, and Type II, featuring β-d-(1→3) and/or (1→6)-galactan. The commercially important larch-derived arabinogalactan belongs to the Type II class. Arabinogalactan is a polysaccharide containing beta-(1,3)-linked galactan backbone with side chains containing arabinose and galactose residues, and often other minor residues.
Lower molecular weight polysaccharides typically exhibit an anti-inflammatory, anti-complement, and anti-allergy effect, while those of higher weights stimulate natural killer (NK) cell cytotoxicity and reticuloendothelial cells. In the case of larch arabinogalactan, molecular weights of the two major fractions are 16,000 and 100,000, which may account for its wide range of biological properties.
Two classes of arabinogalactans are found in nature: plant arabinogalactan and microbial arabinogalactan. In plants, it is often found attached to proteins, and the resulting arabinogalactan protein (AGP) functions as both an intercellular signaling molecule and a glue to seal plant wounds. The microbial arabinogalactan is a major structural component of the mycobacterial cell wall. This reference article focuses on the plant-derived form used as a dietary supplement.
The concentration and distribution of AG varies between Larix species as well as within a single species, but constitutes from 10% to 35% by weight of dry heartwood of a larch tree. The major commercial sources of AG are the North American larch trees, especially Western larch (Larix occidentalis). These trees contain the most substantial amounts of arabinogalactan, ranging from 8% to 25% on a dry weight basis. Larix sibirica, Larix gmelinii, Larix cajanderi Mayr, and Larix olgensis var. Koreana species, growing in the region of Siberia, contain 10%–17% of AG.
Non-limiting examples of arabinogalactan sources include the Western larch (Larix occidentalis), Tamarack (also referred to as the Eastern larch, Larix laricina), Alpine larch (Larix lyallii), European larch (Larix decidua), Mongolian larch (Larix dahurica), Japanese larch (Larix leptolepis), and Siberian larch (Larix siberica).
Arabinogalactan is also widely distributed in other plant species. Numerous other trees, woody plants, and root crops also contain arabinogalactan as part of their cell wall. Other sources include hemlock, black spruce, Douglas fir, cedar, juniper, sugar maple, radishes, carrots, onions, soy bean, and green coffee beans. Additionally, arabinogalactan is found in botanicals, for example echinacea and mistletoe. In plants, it is also a major component of many gums, including gum arabic and gum ghatti.
Larchwood AG is extracted from sawmill residues and butt logs, which are often too deformed or damaged to be useful as lumber, through an aqueous process at 70°C for several days and use of magnesium oxide. Arabinogalactan is a polysaccharide powder derived principally from the wood of the larch tree. It dissolves completely in water or juice and is low in viscosity, making it easy to administer.
Arabinogalactan is commercially available as a powder and a capsule. The powder form can be mixed with water or juice, or it can be added to food. The water-soluble arabinogalactan is also used in food, medicine, ink, and paint. In foods, larch arabinogalactan is used as a stabilizer, binder, and sweetener.
While the isolated compound arabinogalactan is a modern discovery, its source — the larch tree — has been used in traditional medicine for centuries. Native American tribes and early European settlers used larch bark and resin to treat coughs, colds, and infections, as well as to promote wound healing and digestive support.
Historically, indigenous peoples of North America used larch extracts for their health-supporting properties, particularly as a remedy for respiratory issues and as a general tonic. Larch extracts, including arabinogalactan-rich resins, were employed as remedies for respiratory ailments such as coughs, colds, and bronchitis, due to their soothing and expectorant properties. Native American groups also used larch decoctions to promote wound healing and to support digestive health.
The resinous properties of the tree were thought to have cleansing and protective effects on the respiratory and digestive tracts. In European herbal traditions, larch preparations were used as a gentle expectorant, especially in children and the elderly, reflecting its modern role in respiratory and immune health.
The sweetish galactan of the sap was used historically to make baking powder and medicine. The Larix (larch) genus belongs to the Pinaceae (pine) family, which includes spruce, fir, hemlock, pine, and cedar. Larix occidentalis, the Western Larch, is one of about ten species of larch trees and is considered a particularly important commercial and medicinal source.
Arabinogalactan (larch-derived) is composed of galactose and arabinose molecules in a 6:1 ratio, with a small amount of glucuronic acid. The polysaccharide backbone consists of a highly branched structure comprising a backbone of 1,3-linked galactopyranose connected by 1,3-glycosidic linkages, comprised of 3,4,6-, 3,6-, and 3,4- as well as 3-linked residues.
Larch arabinogalactan is resistant to digestion by enzymes in the upper gastrointestinal tract. It reaches the colon where it is slowly fermented by the gastrointestinal microflora and thus promotes the growth of indigenous intestinal microflora such as Bifidobacterium and Lactobacillus acidophilus, similarly to other oligosaccharides.
Particular emphasis in the scientific literature is placed on short-chain fatty acids — the principal microbial fermentation products of dietary fibers — that serve as key mediators between symbiotic microbiota and host immune responses. The mechanisms by which these metabolites modulate immune cell populations, including T lymphocytes, macrophages, dendritic cells, and NK cells, are described, alongside their effects on intestinal barrier function and systemic immunity.
Arabinogalactan consistently enriches Bifidobacterium and Gemmiger across donors, with Bifidobacterium also responding to galactose and Gemmiger and Blautia stimulated by arabinose, the two monosaccharide components of arabinogalactan. Unlike broad-spectrum prebiotics such as inulin, which are utilized by a wide range of gut microbes, arabinogalactan shows a narrower specificity, primarily stimulating B. longum and a few other taxa. This targeted effect may enable more precise modulation of microbiota composition.
Coculture experiments revealed that B. longum not only degraded arabinogalactan efficiently but also supported the growth of non-degrading species via metabolic cross-feeding. These cooperative interactions highlight B. longum as a keystone species in arabinogalactan utilization and suggest broader community-level benefits from its activity. Together, these findings demonstrate arabinogalactan's bifidogenic effect and its potential to promote functionally important microbes within the gut ecosystem.
Different hypotheses can be envisaged as larch arabinogalactan can possibly act indirectly through microbiota-dependent mechanisms and/or have a direct effect on the immune system via the gut-associated lymphoid tissue (GALT).
Cultures of human peripheral blood mononuclear cells (PBMC) as well as cultures of preseparated peripheral non-adherent cells (PNAC) and monocytes showed enhancement of natural killer (NK) cytotoxicity against K562 tumor cells when pretreated with arabinogalactan from Larix occidentalis for 48–72 hours. Arabinogalactan-mediated enhancement of NK cytotoxicity was not initiated directly but was found to be governed by the cytokine network. Generally, arabinogalactan pretreatment induced an increased release of interferon gamma (IFN-γ), tumor necrosis factor alpha, interleukin-1 beta (IL-1β), and IL-6, but only IFN-γ was involved in enhancing NK cytotoxicity.
Low to middle molecular weight (5,000–50,000) arabinogalactan polysaccharides isolated from larch and non-larch sources have been reported to have immunostimulating properties, including the ability to activate phagocytosis and potentiate reticuloendothelial system activity. Several arabinogalactans (isolated from non-larch sources) have also been reported to have anti-complement activity.
The receptor specificity of arabinogalactan is not well characterized. Initial information obtained from comparative studies indicated that arabinogalactan presumably interacts with a receptor that showed specificity for an NK-cytotoxicity-enhancing oligosaccharide from Viscum album extracts, since the action of both components was not synergistic but rather competitive.
The asialoglycoprotein receptor (ASGPR) is present in high density on the surface of liver hepatocytes and exhibits receptor-mediated endocytosis, showing selective uptake of moieties with terminal galactose or galactosamine residues. Intravenous injection of radiolabeled arabinogalactan (4 mg/kg) in rats resulted in 52.5% of the dose being present in the liver, while prior injection of asialofetuin reduced hepatic radioactivity to 3.54%. This property has led to active research into arabinogalactan as a liver-targeted drug delivery scaffold.
Popular ligands for ASGPR-mediated targeting include carbohydrate polymers, arabinogalactan, and pullulan. In one experimental model, arabinogalactan was anchored to nanoparticles for ASGPR targeting, enabling high liver uptake with a hepatocyte:nonparenchymal cell ratio of 85:15, and the combination of pullulan and arabinogalactan exhibited an additive effect implying high hepatocyte accumulation.
In cell and animal models, larch arabinogalactan is capable of enhancing natural killer cells and macrophages as well as the secretion of pro-inflammatory cytokines. The translation of these mechanistic findings into human clinical evidence has been a principal focus of research.
In a placebo-controlled, double-blind, randomized clinical trial, the effect of a proprietary larch arabinogalactan preparation on the incidence of common colds and its effect on cold symptoms was compared to placebo. A total of 199 healthy participants who had a self-reported cold infection rate of three in 6 months were randomly assigned to receive a total of either 4.5 g of an arabinogalactan preparation (n = 101) or placebo (n = 98) over a period of 12 weeks. The participants documented each common cold episode in a diary and rated 10 predefined infection symptoms on a 4-point rating scale during an infection period.
In the full analysis set (FAS), arabinogalactan tended to decrease the incidence of common cold (p = 0.055). The number of participants affected by a cold was significantly reduced by arabinogalactan supplementation (p = 0.038). Concerning the per protocol (PP) collective, the incidences of common cold (p = 0.040) and the number of participants affected by the infection (p = 0.033) were significantly fewer after arabinogalactan compared to placebo consumption. The supplementation with an arabinogalactan preparation reduced the number of common cold episodes by 23%, which suggests an immunomodulatory effect of arabinogalactan. However, the severity of symptoms at episode start as experienced by the participants was significantly higher after arabinogalactan supplementation (p = 0.028), an anomalous finding warranting further investigation. The treatment was well tolerated with no significant differences between the study groups.
A randomized, double-blind, placebo-controlled, parallel-group pilot study tested whether ingestion of a proprietary arabinogalactan extract (ResistAid™) would selectively enhance the antibody response to the pneumococcal (pneumonia) vaccine in healthy adults. This study included 45 healthy adults who had not previously been vaccinated against Streptococcus pneumoniae. The volunteers began taking the study product or placebo at a daily dosage of 4.5 g at the screening visit and continued over the entire 72-day study period. After 30 days, the subjects received the 23-valent pneumococcal vaccine. The proprietary arabinogalactan extract (ResistAid™) increased the antibody response of healthy volunteers to the 23-valent pneumococcal vaccine compared to placebo.
A similar study performed by the same research group compared the effectiveness of the ResistAid® ingredient at a daily dose of 1.5 g to a placebo, and demonstrated a significant increase in IgG antibody response to tetanus vaccine, while no improvement was observed following influenza vaccine. Improvements of serum antigen-specific IgG and IgE response to Streptococcus pneumoniae and tetanus vaccination, suggesting a B cell–dependent mechanism, have been reported in vaccination studies with larch arabinogalactan, while the absence of response following influenza vaccination suggests the involvement of a T cell–dependent mechanism.
These results taken together suggest that larch arabinogalactan can improve immunity by decreasing infections and improving immunoglobulin response following a standardized immune challenge. These observations suggest a role for larch arabinogalactan in the improvement of cold infections, although the mode of action remains to be further explored.
Arabinogalactan's effects on the immune system have been investigated through multiple human studies with different objectives, and results taken together suggest that larch arabinogalactan can improve immunity by decreasing infections and improving immunoglobulin response following a standardized immune challenge. Overall, the human evidence base for immune support is preliminary-to-moderate in strength. Only a limited number of randomized controlled trials exist, the participant numbers are small to moderate, and the commercially funded nature of several of the key studies introduces potential bias. Furthermore, there is no good scientific evidence to support its use for influenza (flu) or ear infection (otitis media).
ResistAid arabinogalactan modulates the gut microbiome by significantly decreasing Firmicutes and increasing Bacteroidetes and Bifidobacterium abundance. In an in vitro fermentation study, the degradation of larch arabinogalactan by gut microbiota was characterized by investigating changes in microbiota composition and the production of short-chain fatty acids, lactic acid, succinic acid, and volatile organic metabolites. During the fermentation, pH decreased continuously, along with the accumulation of organic acids, especially acetic acid and lactic acid. Larch arabinogalactan was degraded by gut microbiota, and beneficial metabolites were produced.
Arabinogalactan is classified as a soluble dietary fiber, meaning it resists digestion in the upper gastrointestinal tract and ferments in the colon, where it serves as a prebiotic, stimulating the growth of beneficial bacteria like Lactobacillus and Bifidobacterium. Its fermentation also produces short-chain fatty acids (SCFAs) like butyrate, which nourish the intestinal lining and help maintain the gut barrier.
The majority of evidence for prebiotic effects derives from in vitro fermentation models and a limited number of human trials. While the bifidogenic effect is consistently observed across studies, including recent ex vivo work with human fecal samples, large-scale randomized controlled trials establishing definitive clinical outcomes (e.g., reduced incidence of gastrointestinal disease) are lacking. The mechanistic evidence is well-established; clinical translation remains an active area.
A distinct area of research concerns arabinogalactan's role as a hepatocyte-targeting agent in drug delivery systems. Asialoglycoprotein receptors (ASGPR) are hepatocyte-bound receptors which exhibit receptor-mediated endocytosis for galactose-specific moieties. Arabinogalactan, a liver-specific high galactose-containing branched polysaccharide, has been investigated as a ligand for this receptor. This remains a preclinical research area with no approved human applications to date.
Medicinally, arabinogalactan has been used for several purposes including complexation with drug molecules to increase their bioavailability. This application, particularly studied with nonsteroidal anti-inflammatory drugs in Russian research, remains largely at the investigational stage.
Arabinogalactan in powder form is typically dosed in tablespoons at a concentration of approximately 4–5 grams per tablespoon.
Immune-stimulating effects of larch arabinogalactan extracted from Larix occidentalis were evaluated in a randomized, double-blind, placebo-controlled, 4-week clinical trial. Twenty-one healthy male volunteers (22–45 years) were randomized to one of six treatment groups or placebo, three subjects in each group, of whom 19 (90%) completed for inclusion in outcome analysis. Three concentration grades of larch arabinogalactan in two doses, 1.5 g/day and 4.5 g/day, were tested.
In the clinical trial on common cold reduction, a total of 199 healthy participants were randomly assigned to receive either 4.5 g of an arabinogalactan preparation (n = 101) or placebo (n = 98) over a period of 12 weeks.
In the pneumococcal vaccine study, volunteers took the study product or placebo at a daily dosage of 4.5 g over the entire 72-day study period.
A tetanus vaccination study used a daily dose of 1.5 g and demonstrated a significant increase in IgG antibody response.
Doses used in these trials suggest that larch arabinogalactan may improve immune response at a dose as low as 1.5 g/day taken for several weeks; however, more consistent results have been obtained at a dose level of 4.5 g/day over several weeks.
Larch arabinogalactan has been used in numerous clinical studies in humans, with no significant safety issues observed at intakes of up to 30 g daily for up to 6 weeks.
Larch arabinogalactan is generally recognized as safe (GRAS) and is approved by the FDA as a source of dietary fiber and for use in food products. The FDA's listing in 21 CFR 172.610 is based on available evidence supporting its safety for specified food applications, while international expert committees such as JECFA include it in their additive databases, indicating it has been evaluated in accordance with established scientific criteria.
Larch arabinogalactan is likely safe when eaten in food amounts. It is possibly safe when taken in higher doses of 1.5–8.4 grams daily for less than 6 months. It can cause side effects such as bloating and intestinal gas (flatulence). There is not enough reliable information to know if it is safe to use for longer than 6 months or what the side effects might be.
Both acute and long-term toxicity studies in rats and mice reveal no evidence of toxicity. Human consumption is usually without side effects; however, a small percentage of people (<3%) experienced bloating and flatulence, possibly due to the vigorous fermentation of arabinogalactan by intestinal microflora.
Arabinogalactan produced no adverse reactions when administered as single IV doses of 5,000 mg/kg in mice, or as repeat doses of 500 mg/kg/day for 90 days in rats. Lavitol (a dihydroquercetin-rich larch extract) did not cause DNA damage in bone marrow, liver, or peripheral blood cells at a single dose of 2,000 mg/kg or at repeat doses of 15 mg/kg. In another animal study, single doses of 10,000 and 15,000 mg/kg were not lethal.
One preclinical nanoparticle study involving arabinogalactan-decorated drug carrier systems did identify a potential caution: subacute toxicity in rats confirmed the safety of the nanoparticle groups, but histopathological evaluation suggested mild renal toxicity of arabinogalactan-decorated nanoparticles. This finding was in the context of an experimental drug-delivery system rather than oral supplementation and requires careful interpretation.
No pharmacokinetic drug–drug interaction studies specific to oral larch arabinogalactan have been identified in the peer-reviewed literature as of the time of this article. Given its prebiotic fermentation in the colon, it may theoretically alter the bioavailability of concurrently administered orally active drugs, although no human studies have formally characterized this. Because arabinogalactan stimulates multiple components of immune function — including NK cells, macrophages, and cytokine release — individuals receiving immunosuppressive therapy represent a population where concurrent use has not been studied.
Arabinogalactan's most robust evidence base pertains to its role as a prebiotic dietary fiber and its bifidogenic effects in the gut, supported by convergent mechanistic and ex vivo data. Its immunomodulatory properties are supported by several small-to-moderate sized randomized controlled trials in humans, demonstrating statistically significant though modest reductions in common cold incidence and improvements in vaccine-specific antibody responses. The quality and independence of the clinical evidence is limited by small sample sizes, reliance on proprietary commercial preparations (ResistAid™), and manufacturer funding in some studies. Anti-cancer, anti-metastatic, and hepatic drug-delivery applications remain preclinical. No well-powered, independent, phase III clinical trials establishing efficacy for any specific clinical indication have been published.
Condiciones de salud que arabinogalactano puede ayudar a apoyar.
A 12-week clinical study in 507 children aged 3–12 years examined larch arabinogalactan's effect on immune health; children aged 7–9 who consumed LA showed lower illness duration and fewer episodes compared to control groups. This pilot clinical finding, combined with mechanistic data on NK cell activation and prebiotic effects, provides initial scientific support for LA in children's immune health.
In vitro studies demonstrate that arabinogalactan reduces LPS-induced pro-inflammatory cytokines (TNF-α, IL-6, IL-1β) and suppresses NF-κB signaling in intestinal epithelial cells. Human clinical data show modulation of TNF-α levels after LA supplementation, and a combination product containing LA reduced fecal IL-6 and IFN-γ significantly in healthy subjects. Evidence at the chronic systemic inflammation level in humans remains limited to mechanistic and small trials.
A randomized, double-blind, placebo-controlled trial (n=199 adults, 12 weeks) found larch arabinogalactan (4.5 g/day) significantly reduced the number of participants affected by common cold (p=0.038) and decreased cold episodes by approximately 23% in the per-protocol analysis. A second vaccine model study showed enhanced antibody response to the pneumococcal vaccine. The immunostimulatory mechanism remains under investigation but likely involves NK cell activation and gut-associated lymphoid tissue (GALT) pathways.
Arabinogalactan (specifically larch arabinogalactan) is identified as a prebiotic fiber relevant to diverticulitis management that nourishes beneficial bacteria and supports the gut immune system. Authoritative integrative medicine resources for diverticulitis specifically endorse arabinogalactan as a prebiotic fiber supporting microbiome health in the context of diverticular disease.
Arabinogalactan is a soluble polysaccharide fiber, most commonly derived from larch trees, that functions as a prebiotic by selectively stimulating Bifidobacterium and Lactobacillus populations in the gut. It is fermented by colonic bacteria to produce short-chain fatty acids, particularly butyrate. Multiple in vitro and some human studies support its prebiotic classification.
Arabinogalactan is a prebiotic polysaccharide from larch tree (and other plants) that undergoes colonic fermentation to produce short-chain fatty acids and promotes growth of Bifidobacterium and Lactobacillus. It has been recognized by authoritative sources as a dietary fiber supporting gut barrier health through SCFA production and beneficial microbiota stimulation, and it modulates intestinal immune function.
The pivotal 12-week RCT supporting arabinogalactan's respiratory benefits was specifically conducted during the cold season (2010/2011), making its findings directly applicable to seasonal respiratory health. LA significantly reduced cold episode incidence and the number of affected subjects during this high-risk period. The prebiotic-immune axis may confer broader seasonal immune resilience.
Clinical evidence, including a 199-person RCT over 12 weeks, demonstrates that larch arabinogalactan supplementation significantly reduced the incidence and number of participants affected by upper respiratory tract infections. Additional vaccine-response studies further support an immunostimulatory effect relevant to upper respiratory defence. Mechanistic data suggest NK cell enhancement and macrophage activation as contributing pathways.
Arabinogalactan from larch (Larix species) is a prebiotic polysaccharide with immunostimulatory properties including NK cell and macrophage activation. Extracts from Echinacea also contain arabinogalactans contributing to antiviral immune modulation. Clinical studies support its role in reducing frequency of common cold infections.
Sistemas corporales que arabinogalactano puede ayudar a apoyar.
Volver